Paclitaxel is a compound with anti-tumor activity extracted from the Pacific yew tree Taxus brevifolia. Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Structure of 33069-62-4
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
2 g | $199 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|
NCT03779464 | Pancreatic Cancer | Phase 2 | 2019-07-08 | Wuhan Union Hospital, China | Unknown Verified July 2019 by Tao Zhang, Wuhan Union Hospital, China. Recruitment status was Recruiting |
NCT03618758 | Gastric Cancer Stage IV | Phase 1, Phase 2 | 2021-03-09 | Seoul National University Bundang Hospital | Recruiting |
NCT03872141 | Breast Cancer | 2021-05-03 | Yale University | Completed | |
NCT04496544 | Peripheral Arterial Disease | 2020-08-03 | Beth Israel Deaconess Medical Center | Active, not recruiting | |
NCT04159142 | Triple Negative Breast Cancer | Phase 2 | 2019-11-12 | Hebei Medical University Fourth Hospital | Recruiting |
Paclitaxel is a microtubule-stabilizing natural product and a potent ADC cytotoxin employed as an ADC payload in antibody-drug conjugates. Its mechanism of action involves binding to β-tubulin subunits, promoting microtubule polymerization, stabilizing microtubules against depolymerization, and causing mitotic arrest in the G2/M phase. This results in inhibition of cell division and induction of apoptosis in proliferating tumor cells. The chemical structure of Paclitaxel allows covalent conjugation to monoclonal antibodies through cleavable or non-cleavable linkers, facilitating precise intracellular delivery in ADC applications.
Within antibody-drug conjugates, Paclitaxel is linked to antibodies using linker chemistries designed to ensure systemic stability and controlled intracellular payload release. The ADC remains inactive during circulation, minimizing off-target cytotoxicity. Upon receptor-mediated internalization into antigen-expressing tumor cells, enzymatic or chemical cleavage liberates the active Paclitaxel payload. Once released, it stabilizes microtubules, disrupts mitotic spindle formation, and triggers apoptosis. This targeted mechanism ensures cytotoxic effects are confined to tumor cells, enhancing the specificity and reproducibility of tumor-targeted therapy.
Applications of Paclitaxel include incorporation into ADCs targeting both solid tumors and hematologic malignancies with defined antigen expression. Its chemical compatibility with various linker chemistries allows optimization of conjugation efficiency, intracellular release kinetics, and pharmacokinetics. Paclitaxel demonstrates consistent cytotoxic activity in target-expressing tumor cells, supporting the development of ADCs with precise antimitotic activity. Its well-characterized mechanism of microtubule stabilization provides controlled apoptosis induction, making it suitable as a mechanistically robust payload for ADC design and targeted oncology therapy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01447 | Paclitaxel D5 | 1129540-33-5 |
What is Paclitaxel?
Paclitaxel is a well-known microtubule-stabilizing chemotherapeutic agent widely used as a payload in ADCs. It promotes apoptosis by inhibiting microtubule depolymerization, which arrests the cell cycle at the G2/M phase.
25/12/2021
We are interested in how Paclitaxel is used in ADC development.
Paclitaxel is conjugated to antibodies in ADCs to selectively target tumor cells, leveraging its cytotoxic mechanism while minimizing systemic toxicity. It is suitable for preclinical research and development of targeted therapeutics.
29/7/2019
Could you advise which linkers are compatible with Paclitaxel in ADCs?
Paclitaxel can be linked using cleavable or non-cleavable linkers, including peptide-based or ester linkers. Linker choice influences drug release, stability, and pharmacokinetics, which are key in ADC design.
12/8/2022
Dear team, may I ask if BOC Sciences provides Paclitaxel ADC customization?
BOC Sciences offers Paclitaxel ADC services including payload conjugation, linker optimization, and analytical support. Customized solutions enable precise ADC design for preclinical research and targeted therapy studies.
16/9/2018
Dear team, what safety precautions are necessary when handling Paclitaxel?
Paclitaxel is highly cytotoxic and requires strict laboratory safety practices, including PPE, containment, and adherence to handling protocols, to minimize risk during preparation, conjugation, and analysis.
23/12/2018
— Dr. Kevin Wallace, Senior Scientist (USA)
Paclitaxel from BOC Sciences arrived with outstanding purity, crucial for our ADC conjugation projects.
12/8/2022
— Dr. Daniel White, Senior Scientist (USA)
Paclitaxel batches from BOC Sciences consistently meet our purity standards, critical for reproducible ADC payload studies.
23/12/2018
— Ms. Annika Bauer, ADC Research Scientist (Germany)
We appreciated the detailed CoA and QC data accompanying Paclitaxel, which streamlined our laboratory workflow.
16/9/2018
— Dr. Oliver Grant, Biochemist (UK)
Paclitaxel delivered exceptional solubility and stability for conjugation, improving efficiency in our ADC development.
25/12/2021
— Mr. Pierre Moreau, Medicinal Chemist (France)
Technical support and on-time delivery of Paclitaxel were excellent, ensuring we could meet our project timelines.
— Dr. Helena Andersson, Laboratory Head (Sweden)
The quality and documentation of Paclitaxel exceeded expectations, supporting consistent experimental results.
29/7/2019
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.